Clinically suitable approach for gene-mediated therapy of cirrhosis.
Award amount
$224,999Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ADVANTAGENE, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- MPKRJM6FJFL8
- Solicitation number
- PA13-088
- Topic code
- NIAAA
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
- Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
- Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
- Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
- Improved system for producing adenoviral vectors
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
- DEVELOPMENT OF NOVEL PDE4B INHIBITORS TO TREAT ALCOHOL USE DISORDER (SBIR PHASE II)
- SBIR PHASE I - WEARABLE BIOSENSOR THAT QUANTIFIES BLOOD ALCOHOL CONCENTRATION IN REAL TIME
- THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.
- Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
Research funding history
10 SBIR/STTR records share this UEI (2003–2018). Reported award amounts total $12,459,149. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services